Tikva Allocell is a biotechnology company that specializes in next-gen cell therapies.
Tikva Allocell has raised $8.0M in total funding. The most recent round was Series A. The last funding was announced in July 2026.
Tikva Allocell's investors include Kantharos Capital.
Tikva Allocell is headquartered in Singapore, Singapore.
Tikva Allocell is a biotechnology company that specializes in next-gen cell therapies.
Tikva Allocell is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tikva Allocell — Funding & Investors." VCBacked, July 22, 2026, https://www.vcbacked.co/company/tikva-allocell. Accessed September 14, 2026.
VCBacked. (2026). Tikva Allocell — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/tikva-allocell
{{cite web |title=Tikva Allocell — Funding & Investors |url=https://www.vcbacked.co/company/tikva-allocell |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated